Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome.
Identifieur interne : 002F14 ( PubMed/Checkpoint ); précédent : 002F13; suivant : 002F15Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome.
Auteurs : Yasser Awaad [États-Unis] ; Anne Marie Michon ; Sarah MinarikSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2005.
English descriptors
- KwdEn :
- Adolescent, Anticonvulsants (therapeutic use), Child, Demography, Dose-Response Relationship, Drug, Educational Status, Female, Humans, Male, Piracetam (analogs & derivatives), Piracetam (therapeutic use), Prospective Studies, Psychiatric Status Rating Scales, Severity of Illness Index, Tics (drug therapy), Tics (etiology), Tourette Syndrome (complications), Treatment Outcome.
- MESH :
- chemical , analogs & derivatives : Piracetam.
- chemical , therapeutic use : Anticonvulsants, Piracetam.
- complications : Tourette Syndrome.
- drug therapy : Tics.
- etiology : Tics.
- Adolescent, Child, Demography, Dose-Response Relationship, Drug, Educational Status, Female, Humans, Male, Prospective Studies, Psychiatric Status Rating Scales, Severity of Illness Index, Treatment Outcome.
Abstract
Some drugs currently used to treat tics in pediatric patients have drawbacks, including the risk of side effects. New therapeutic options with better safety profiles are needed. Levetiracetam is an antiepileptic drug with atypical mechanisms of action that might be beneficial for this indication. We evaluated the effects of levetiracetam on motor and vocal tics, behavior, and school performance in children and adolescents with tics and Tourette syndrome (TS). Sixty patients, < or =18 years of age, with tics and TS were enrolled in this prospective, open-label study. The initial starting dose of levetiracetam was 250 mg/day. The dosage was titrated over 3 weeks to 1,000 to 2,000 mg/day. Clinical outcomes were assessed with the Clinical Global Impression Scale, Yale Global Tic Severity Scale, and Revised Conners' Parent Rating Scale. Behavior and school performance were also recorded. All 60 patients showed improvements based on all of the scales used, and 43 patients improved with regard to behavior and school performance. Levetiracetam was generally well tolerated. Three patients discontinued treatment because of exaggeration of preexisting behavioral problems. Levetiracetam may be useful in treating tics in children and adolescents. Given its established safety profile, levetiracetam is a candidate for evaluation in a well-controlled trial.
DOI: 10.1002/mds.20385
PubMed: 15704204
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:15704204Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome.</title><author><name sortKey="Awaad, Yasser" sort="Awaad, Yasser" uniqKey="Awaad Y" first="Yasser" last="Awaad">Yasser Awaad</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pediatrics, Oakwood Healthcare System, University of Michigan Medical School, 21031 Michigan Avenue, Dearborn, MI 48124, USA. yasser.awaad@oakwood.org</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pediatrics, Oakwood Healthcare System, University of Michigan Medical School, 21031 Michigan Avenue, Dearborn, MI 48124</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Michon, Anne Marie" sort="Michon, Anne Marie" uniqKey="Michon A" first="Anne Marie" last="Michon">Anne Marie Michon</name></author><author><name sortKey="Minarik, Sarah" sort="Minarik, Sarah" uniqKey="Minarik S" first="Sarah" last="Minarik">Sarah Minarik</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="doi">10.1002/mds.20385</idno><idno type="RBID">pubmed:15704204</idno><idno type="pmid">15704204</idno><idno type="wicri:Area/PubMed/Corpus">003156</idno><idno type="wicri:Area/PubMed/Curation">003156</idno><idno type="wicri:Area/PubMed/Checkpoint">002F14</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome.</title><author><name sortKey="Awaad, Yasser" sort="Awaad, Yasser" uniqKey="Awaad Y" first="Yasser" last="Awaad">Yasser Awaad</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pediatrics, Oakwood Healthcare System, University of Michigan Medical School, 21031 Michigan Avenue, Dearborn, MI 48124, USA. yasser.awaad@oakwood.org</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pediatrics, Oakwood Healthcare System, University of Michigan Medical School, 21031 Michigan Avenue, Dearborn, MI 48124</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Michon, Anne Marie" sort="Michon, Anne Marie" uniqKey="Michon A" first="Anne Marie" last="Michon">Anne Marie Michon</name></author><author><name sortKey="Minarik, Sarah" sort="Minarik, Sarah" uniqKey="Minarik S" first="Sarah" last="Minarik">Sarah Minarik</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Anticonvulsants (therapeutic use)</term><term>Child</term><term>Demography</term><term>Dose-Response Relationship, Drug</term><term>Educational Status</term><term>Female</term><term>Humans</term><term>Male</term><term>Piracetam (analogs & derivatives)</term><term>Piracetam (therapeutic use)</term><term>Prospective Studies</term><term>Psychiatric Status Rating Scales</term><term>Severity of Illness Index</term><term>Tics (drug therapy)</term><term>Tics (etiology)</term><term>Tourette Syndrome (complications)</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Piracetam</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anticonvulsants</term><term>Piracetam</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Tourette Syndrome</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Tics</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Tics</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Child</term><term>Demography</term><term>Dose-Response Relationship, Drug</term><term>Educational Status</term><term>Female</term><term>Humans</term><term>Male</term><term>Prospective Studies</term><term>Psychiatric Status Rating Scales</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Some drugs currently used to treat tics in pediatric patients have drawbacks, including the risk of side effects. New therapeutic options with better safety profiles are needed. Levetiracetam is an antiepileptic drug with atypical mechanisms of action that might be beneficial for this indication. We evaluated the effects of levetiracetam on motor and vocal tics, behavior, and school performance in children and adolescents with tics and Tourette syndrome (TS). Sixty patients, < or =18 years of age, with tics and TS were enrolled in this prospective, open-label study. The initial starting dose of levetiracetam was 250 mg/day. The dosage was titrated over 3 weeks to 1,000 to 2,000 mg/day. Clinical outcomes were assessed with the Clinical Global Impression Scale, Yale Global Tic Severity Scale, and Revised Conners' Parent Rating Scale. Behavior and school performance were also recorded. All 60 patients showed improvements based on all of the scales used, and 43 patients improved with regard to behavior and school performance. Levetiracetam was generally well tolerated. Three patients discontinued treatment because of exaggeration of preexisting behavioral problems. Levetiracetam may be useful in treating tics in children and adolescents. Given its established safety profile, levetiracetam is a candidate for evaluation in a well-controlled trial.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">15704204</PMID><DateCreated><Year>2005</Year><Month>06</Month><Day>06</Day></DateCreated><DateCompleted><Year>2005</Year><Month>07</Month><Day>29</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>6</Issue><PubDate><Year>2005</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome.</ArticleTitle><Pagination><MedlinePgn>714-8</MedlinePgn></Pagination><Abstract><AbstractText>Some drugs currently used to treat tics in pediatric patients have drawbacks, including the risk of side effects. New therapeutic options with better safety profiles are needed. Levetiracetam is an antiepileptic drug with atypical mechanisms of action that might be beneficial for this indication. We evaluated the effects of levetiracetam on motor and vocal tics, behavior, and school performance in children and adolescents with tics and Tourette syndrome (TS). Sixty patients, < or =18 years of age, with tics and TS were enrolled in this prospective, open-label study. The initial starting dose of levetiracetam was 250 mg/day. The dosage was titrated over 3 weeks to 1,000 to 2,000 mg/day. Clinical outcomes were assessed with the Clinical Global Impression Scale, Yale Global Tic Severity Scale, and Revised Conners' Parent Rating Scale. Behavior and school performance were also recorded. All 60 patients showed improvements based on all of the scales used, and 43 patients improved with regard to behavior and school performance. Levetiracetam was generally well tolerated. Three patients discontinued treatment because of exaggeration of preexisting behavioral problems. Levetiracetam may be useful in treating tics in children and adolescents. Given its established safety profile, levetiracetam is a candidate for evaluation in a well-controlled trial.</AbstractText><CopyrightInformation>(c) 2005 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Awaad</LastName><ForeName>Yasser</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Oakwood Healthcare System, University of Michigan Medical School, 21031 Michigan Avenue, Dearborn, MI 48124, USA. yasser.awaad@oakwood.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michon</LastName><ForeName>Anne Marie</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Minarik</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>230447L0GL</RegistryNumber><NameOfSubstance UI="C026098">etiracetam</NameOfSubstance></Chemical><Chemical><RegistryNumber>ZH516LNZ10</RegistryNumber><NameOfSubstance UI="D010889">Piracetam</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000927">Anticonvulsants</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003710">Demography</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004522">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010889">Piracetam</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000031">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011569">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020323">Tics</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005879">Tourette Syndrome</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>2</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>7</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>2</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.20385</ArticleId><ArticleId IdType="pubmed">15704204</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Michigan</li></region></list><tree><noCountry><name sortKey="Michon, Anne Marie" sort="Michon, Anne Marie" uniqKey="Michon A" first="Anne Marie" last="Michon">Anne Marie Michon</name><name sortKey="Minarik, Sarah" sort="Minarik, Sarah" uniqKey="Minarik S" first="Sarah" last="Minarik">Sarah Minarik</name></noCountry><country name="États-Unis"><region name="Michigan"><name sortKey="Awaad, Yasser" sort="Awaad, Yasser" uniqKey="Awaad Y" first="Yasser" last="Awaad">Yasser Awaad</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F14 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002F14 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:15704204
|texte= Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:15704204" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |